A study found that blocking MASTL expression in colorectal cancer cells led to increased sensitivity to 5FU chemotherapy and reduced expression of SURVIVIN and BCL-XL by activating the Wnt/β-catenin signaling pathway (Uppada et al. 2018). Here, BCL2L1 is linked to colorectal cancer.